Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.
A user is considering a hair loss treatment lotion containing minoxidil, adenosine, caffeine, melatonin, and azelaic acid, questioning the interaction between caffeine and adenosine receptors. Another user suggests adding a topical anti-DHT ingredient like spironolactone, noting it should not be taken orally by men.
Vitamin D tests like D2, D3, and 25-hydroxyvitamin D are discussed before starting hair treatment. Vitamin D can be obtained from food, but overdose has side effects.
The conversation discusses using topical liposomal finasteride for hair loss, with concerns about high DHT levels. The user's DHT level is above the normal range, which may affect hair health.
The user has been using oral finasteride for 15 months and oral minoxidil for 6 months, and developed alopecia areata, for which a dermatologist prescribed calcipotriol/betamethasone. The treatment is helping, but the user is experiencing another shedding phase and is concerned about the effects of the steroid cream and the cause of hair loss.
The user is using Minoxidil, finasteride, Nizoral, and dermarolling for hair loss but is not seeing results. They are considering trying a product called "capilia longa" for beard growth and are questioning its effectiveness.
The conversation is about choosing a second shampoo to use alongside Nizoral for hair loss treatment. Suggestions include Nioxin, baby shampoo, Lipogaine, and Revita, with some users recommending letting the shampoo sit for a few minutes before rinsing.
Using finasteride and peptides, including GHK-Cu, improved hair thickness and regrowth. The user also used a KLOW blend and CJC/IPA for better sleep and recovery.
The user plans to test for DHT, total testosterone, free testosterone, E2, SHBG, and prolactin while supplementing with vitamin D and monitoring ferritin levels. They are experiencing hairline thinning and are seeking advice on whether their approach is excessive or lacking.
Analyzing data on pyrilutamide, a potential hair loss treatment, as well as the effectiveness of other treatments such as Minoxidil, Finasteride, and RU58841.
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.
Reducing the dose of Pyrilutamide from 5mg to 2.5mg may still maintain hair loss results, but effectiveness can vary. Users discuss the cost and dosage implications, with some cautioning against reducing the dose due to its dose-dependent nature.
Clascoterone cream can be used on the scalp, but it may not be effective due to its dosage. AR antagonists like clascoterone are generally less effective than 5AR inhibitors for hair loss.
A 26-year-old male with grade 3 hair loss is using 2.5 mg oral minoxidil, 1 mg finasteride, 5% minoxidil, ketoconazole shampoo, and kLM d3. He plans to post progress pictures every 6 weeks and is seeking suggestions.
The user is sharing their progress with hair loss treatments including finasteride, minoxidil, keto shampoo, and dermastamping. Other users are expressing positive reactions and discussing the benefits of keto shampoo and minoxidil.
Loose-Message9596 has been experiencing hair loss for 3-4 years, initially due to low ferritin and vitamin D levels, and has tried treatments like vitamins, System 4, and PRP therapy. They are considering starting finasteride and minoxidil but are unsure due to their relatively low DHT level of 425.
The conversation is about making a topical solution from clascoterone powder, with references to using a RU58841 mixing guide for guidance. Concerns about product authenticity and bulk purchase requirements are also discussed.
Nizoral 2% is popular for maintaining scalp health and reducing inflammation, though its effectiveness for hair loss is debated. Some users combine it with finasteride for better results, while others find it drying or ineffective.
Zinc pyrithione and piroctone olamine are effective for reducing hair shedding, possibly more so than ketoconazole. There is a concern about zinc pyrithione shampoo interfering with minoxidil, but it's unclear if this is proven.
Baricitinib, approved for alopecia areata, might be considered for treating receding hairlines. The discussion is about the possibility of an over-the-counter topical version for androgenic alopecia.
The user is experiencing hair loss and is considering using topical minoxidil and finasteride due to concerns about liver health, specifically elevated ALT levels from fatty liver. They are advised to start with topical treatments while continuing weight loss and dietary changes to improve liver function.
A user is trying 2-deoxy-D-ribose with distilled water for hair growth, observing new hair and skin pigmentation changes. Others compare it to Minoxidil, expressing interest and caution about its effectiveness and safety.
Alfatradiol is used by some for hair loss, often alongside treatments like finasteride, RU58841, and minoxidil, but its effectiveness is unclear. Some users report no significant improvement, while others note reduced sebum production but experience side effects like gallbladder pain.
A 32-year-old male shares his 5-year progress using finasteride, minoxidil, RU58841, and ketoconazole for hair loss. Despite consistent use, he feels his hair isn't as thick as before and is concerned about continued shedding and hairline miniaturization.
A user shared their 9-month progress using RU58841 at 2% daily for hair regrowth, initially starting at 5% but reducing the dose due to early signs of gynecomastia, which has since mostly resolved. They achieved their goal of regrowing hair at the temples and hairline.
A user is seeing good results with RU58841 for hair loss, noting reduced shedding and thicker hair. They plan to use pumpkin seed oil as a solvent to avoid water content, which they believe reduces the effectiveness of anti-androgens.
The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.